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Abstract: 
 Prophylactic eradication of central nervous system (CNS) leukaemia is the current 
standard of care in treating childhood acute lymphoblastic leukaemia (ALL). This is 
conventionally achieved through regular lumbar punctures with intrathecal injections of 
methotrexate into the cerebrospinal fluid (CSF). Ommaya reservoirs are subcutaneous 
implantable devices that provide a secure route of drug delivery into the CSF via an 
intraventricular catheter. They are an important alternative in cases where intrathecal injection 
via lumbar puncture is difficult. Among UK Paediatric Principal Treatment centres for ALL 
we found considerable variation in methotrexate dosing when using an Ommaya reservoir. We 
review the current safety and theoretical considerations when using Ommaya reservoirs and 
evidence for methotrexate dose adjustments via this route. We conclude by summarising the 
pragmatic consensus decision to use 50% of the conventional intrathecal dose of methotrexate 
when it is administered via Ommaya reservoir in front-line ALL therapy.  
Key points: 
1. Ommaya reservoirs can be used to deliver chemotherapy to the central nervous system 
via an implanted intraventricular catheter. 
2. A survey of UK Paediatric Principal Treatment centres revealed a wide range of dosing 
of chemotherapy agents when converting from intrathecal to intraventricular (Ommaya) 
delivery. 
3. Review of the literature supports reduced dosing when CNS-directed therapy is given 
by Ommaya reservoir in place of conventional intrathecal therapy. 
 
1. Introduction: 
The central nervous system (CNS) remains an important sanctuary site for childhood 
acute lymphoblastic leukaemia (ALL). [1]. Although overt CNS infiltration is only seen in 2-
5% of children at initial diagnosis, approximately 40% of relapses involve the CNS [2, 3]. 
Without CNS-directed chemotherapy up to 75% of patients will relapse within the CNS [4], 
and yet no reliable predictors of relapse-risk have been identified. Both clinical observations 
and experimental models suggest that subclinical CNS infiltration is likely to be present in the 
majority of patients at initial diagnosis.  For this reason, all patients currently receive 
“prophylactic” CNS treatment regardless of the presence of detectable leukaemia in samples 
of cerebrospinal fluid (CSF). This treatment is potentially toxic to the developing brain and can 
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produce neurocognitive impairment [5]. In addition, relapse within the CNS can be refractory 
to conventional chemotherapy and/or bone marrow (BM) transplantation [1].  CNS control is 
now often achieved using intrathecal chemotherapy (delivered directly into the circulating CSF 
via lumbar puncture) [4, 6]) and systemic drugs with good CNS penetration, instead of cranial 
irradiation. This change followed observation of the long-term adverse effects of cranial 
irradiation, such as development of secondary cancers, endocrinopathies and neurocognitive 
impairment [1]. Methotrexate is the commonest intrathecal agent used in ALL, either alone or 
in combination with cytarabine and hydrocortisone (so called triple therapy). Several studies 
have demonstrated comparable efficacy and similar rates of CNS relapse using intrathecal 
methotrexate or triple therapy, compared with results using cranio-spinal irradiation [7-9]. 
Consequently, many trial groups now use intensive intrathecal chemotherapy as the standard 
of care for prophylaxis and treatment of CNS leukaemia, whilst others reserve cranial 
irradiation for those at highest risk of CNS relapse. 
Clinically, there are two methods of delivering CNS-directed chemotherapy. 
Conventionally, intrathecal lumbar puncture is used to administer chemotherapy into the 
lumbosacral CSF space. Alternatively, chemotherapy can be administered via an implantable 
Ommaya reservoir, a small device comprising a capsule, situated between the cranium and 
overlying skin connected to a catheter communicating directly with one of the lateral ventricles 
[10]. The Ommaya reservoir allows for repeated CSF sampling and for chemotherapy to be 
delivered directly into the cerebral ventricles, rather than relying on CSF flow from the lumbar 
to the cranial regions. While lumbar punctures are the standard route of delivery for intrathecal 
chemotherapy, Ommaya reservoirs remain an important alternative for CNS access. Examples 
of situations where an Ommaya reservoir might be used include; patients where spinal anatomy 
or obesity make lumbar punctures technically challenging, and patients with hydrocephalus, 
microcephaly or known abnormalities of CSF flow [11]. In addition, for some patients with 
refractory CNS relapse use of an Ommaya facilitates frequent reliable delivery of adequate 
doses of CNS-therapy without the need for repeated general anaesthesia. 
 
Although the intrathecal dose of methotrexate is well established and standardised, 
there is a lack of definitive evidence regarding the optimal dosing of chemotherapy when given 
as an intraventricular injection via an Ommaya reservoir. We surveyed all UK Paediatric 
Principal Treatment Centres and found considerable variation in the dose of intraventricular 
chemotherapy administered to children with ALL, ranging from 100% dosing (i.e. identical to 
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the calculated intrathecal dose) to 20% dosing (figure 1). There is a clinical need for guidance 
in this area, as methotrexate-induced neurotoxicity remains a significant side effect of CNS-
directed therapy, whilst under-dosing of methotrexate may increase CNS relapse. In this article, 
we review important safety and efficacy considerations for methotrexate administered via 
Ommaya reservoir and discuss the clinical and pharmacological differences between 
intrathecal and intraventricular administration in children with ALL. We conclude by 
summarising a consensus decision for future dosing of intraventricular methotrexate in ALL.  
2. Clinical advantages and limitations of the Ommaya reservoir: 
The advantages and limitations of Ommaya reservoirs are discussed below 
(summarised in table 1). 
2.1 Safety: 
 Most published studies and case series using Ommaya reservoirs for intraventricular 
chemotherapy in meningeal leukaemia are now more than 30 years old. Studies reporting on 
Ommaya reservoirs in ALL are very rare in contemporary literature. Furthermore, a 
randomised controlled trial (RCT) comparing intraventricular chemotherapy with intrathecal 
chemotherapy in ALL has never been performed. It appears that use of Ommaya reservoirs for 
CNS leukaemia declined during the 1980s, probably due to safety concerns relating to 
relatively common CNS infections and neurological complications associated with their early 
use. In modern treatment regimens, Ommaya reservoirs are generally reserved for patients with 
difficult access to the lumbar spine, or in those with abnormal CNS anatomy, such as 
hydrocephalus, microcephaly or known abnormal CSF flow [11]. It is therefore challenging to 
define precisely the safety of Ommaya reservoirs in unselected children with leukaemia. 
However, Ommaya reservoirs are also used in treatment of paediatric brain tumours. While 
direct comparison between these two patient populations should be approached with caution, 
recent case series provide useful data on contemporary short-term complication rates.  
2.2 Bacterial infection: 
Peyrl and colleagues describe in detail their meticulous aseptic approach to 
administering intraventricular chemotherapy to children with CNS tumours via Ommaya 
reservoir [12]. Their approach resulted in just one child out of 98 developing an Ommaya-
related CNS infection over 20 years. In addition to strict adherence to aseptic technique when 
delivering intraventricular chemotherapy, they also administered prophylactic antibiotics prior 
to surgical incision and for 3-5 days post-operatively. Modern neurosurgical technologies were 
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employed to aid catheter placement and MRI studies of the brain and spinal cord were 
conducted prior to insertion, and the position of the catheter tip was confirmed on CT or MRI 
scan, post-operatively. This group also avoided using the reservoir for 5 days post-operatively 
to reduce the risk of retrograde flow of intraventricular therapies through the catheter tract and 
to promote wound healing around the reservoir. This approach resulted in very low rates of 
Ommaya-related CNS infection in a large cohort of paediatric cancer patients. It should be 
noted that this was a case series rather than a comparative study so the contribution of each 
individual component to the low infection rates is unknown. Another large retrospective 
analysis of 616 adult and paediatric cancer patients with Ommaya reservoirs report infection 
rates of 5.5% [13]. Taken together, these reports demonstrate a considerable reduction in the 
incidence of bacterial infections associated with Ommaya reservoirs, compared with earlier 
reports, which ranged between 15-41% [14-16]. Importantly, the studies agree that increasing 
numbers of intra-Ommaya injections correlate with an increased risk of infection. However, 
Peyrl and colleagues virtually eliminated this risk with a rigorous aseptic protocol for device 
access [12].  
2.3 Misplaced Ommaya catheters: 
In older studies, Ommaya catheters were occasionally displaced into the brain 
parenchyma, often leading to severe complications, such as focal leukoencephalopathy [17-19]. 
Modern neurosurgery by comparison benefits from significant improvements in intraoperative 
neurosurgical technologies and perioperative neuroimaging [20-22]. These advances should 
considerably reduce the risk of Ommaya-catheter malposition and allow for accurate 
assessment of catheter-tip position prior to chemotherapy administration. These improvements 
optimise safe Ommaya reservoir placement and are likely to reduce significantly the adverse 
effects of using these implantable devices for administering CNS-directed chemotherapy.   
2.4 Neurotoxicity: 
Methotrexate-induced neurotoxicity has been extensively reported in children treated 
for ALL.  It has a variety of clinical presentations from an acute encephalopathy, seizures or a 
stroke-like syndrome to chronic neurocognitive deficits. Stroke-like syndrome is seen in 1-4% 
of children treated in modern protocols [23-25] and presents 2 to 14 days post-exposure to 
methotrexate with fluctuating focal neurological signs, such as; encephalopathy, seizures, 
expressive dysphasia, and hemiparesis [24-27]. MRI studies of symptomatic children typically 
demonstrate patchy leukoencephalopathy. Interestingly, MRI studies in asymptomatic children 
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receiving methotrexate as CNS-prophylaxis demonstrate radiological leukoencephalopathy in 
21-27% of cases, suggesting high rates of subclinical white matter damage [24, 26]. One study 
indicated that children with subclinical leukoencephalopathy are more likely to have long-term 
neurobehavioral deficits than patients on identical treatment protocols without MRI evidence 
of leukoencephalopathy [26]. Additional studies have investigated neurocognitive functioning 
in children treated with contemporary chemotherapy-only treatment regimens [5]. Some 
studies observe that while most children generally have age-appropriate neurocognition, those 
treated with higher-intensity protocols are at greater risk of long-term deficits in neurocognitive 
functioning [28, 29] and executive function [30]. Another large follow-up study supports these 
observations in a cohort of long-term survivors but did not identify an association with 
treatment intensity [31]. The relationship between methotrexate drug levels and neurotoxicity 
is complex. There is evidence that the intensity of methotrexate exposure is associated with 
neurotoxicity [32] and one study found an association between individual methotrexate 
exposure levels (area under the curve) and leukoencephalopathy on MRI scanning [24]. On the 
other hand, there is no clear dose response, patients with stroke-like syndrome can usually be 
re-exposed to the same dose without recurrence, and it is likely that additional risk factors are 
present [33].     
There is no evidence that intraventricular methotrexate produces higher rates of 
neurotoxicity than intrathecal methotrexate, although this has not been formally tested in 
randomised trials. However, the known higher methotrexate concentration in the ventricular 
CSF when identical doses are given intrathecally or via the intraventricular route (discussed in 
detail below) raises a theoretical concern of enhanced neurotoxicity and supports the need to 
consider dose reduction via the intraventricular route. 
 
2.5 Systemic side effects with intraventricular chemotherapy: 
Owing to slow diffusion of methotrexate across the blood-brain barrier, CSF can act as 
a reservoir for systemic drug perfusion, whereby low concentrations of methotrexate 
continuously enter the circulation from the CSF [34-36]. Indeed, systemic exposure as 
measured by red cell accumulation of methotrexate appears greater with IT MTX than the same 
dose given orally [37] and timing of intrathecal MTX can influence systemic ALL responses 
as measured by day 8 peripheral blast count [38]. Furthermore, long exposure to subtherapeutic 
levels of methotrexate can cause myelosuppression. Leucovorin is sometimes used to alleviate 
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myelosuppression without apparent compromise of methotrexate efficacy [39]. Again, 
theoretically the high concentrations of methotrexate achieved using Ommaya reservoirs may 
potentiate these systemic effects if no corresponding dose reduction is used. 
 
2.6 Clinical advantages of Ommaya reservoir: 
Ommaya reservoirs are a very efficient method of accessing the CNS, compared with 
repeated lumbar punctures. Following neurosurgical placement, the procedure of sampling 
CSF and then administering chemotherapy is straightforward and relatively painless [12, 14]. 
Furthermore, while training in aseptic use is of paramount importance, accessing the Ommaya 
reservoir is technically simple and does not require general anaesthesia. Some children with 
abnormal spinal anatomy present a recurrent challenge and an emerging clinical indication for 
Ommaya reservoirs is the increasing prevalence of obese and severely obese children [40, 41], 
which makes repeated lumbar CSF access difficult. With a meticulous aseptic approach, 
Ommaya reservoirs provide a safe, effective alternative to repeated lumbar puncture. 
Interestingly in one small study it was reported that patients receiving alternating intrathecal 
and intraventricular chemotherapy overwhelmingly preferred the Ommaya route [42]. 
 
3. Efficacy of intraventricular methotrexate versus intrathecal methotrexate in 
treating ALL: 
No published RCTs have compared the two routes. However, two small studies indicate 
possible superior efficacy of intraventricular methotrexate for treatment of CNS ALL. Bleyer 
and colleagues published the first study in 1979 which included 10 children who developed 
CNS relapse despite monthly intrathecal methotrexate maintenance treatment [43]. The 
children were re-induced and remission maintained using intraventricular methotrexate via an 
Ommaya reservoir. Seven of the eight evaluable children had significantly longer remissions 
using intraventricular methotrexate, compared with intrathecal methotrexate. The median CNS 
remission duration with intraventricular methotrexate was 475 days, compared with 286 days 
during prior treatment with intrathecal methotrexate (p<0.05). Equivalent doses of 
methotrexate were used for both routes of administration (12-15mg/m2, max dose 18mg), 
unless participants had previous methotrexate-related neurotoxicity, in which case the dose was 
reduced (averaging 8mg/m2). There was one infection in the Ommaya reservoir group; a 
Staphylococcus epidermidis meningitis which was successfully treated with intraventricular 
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and intravenous methicillin and which allowed the device to remain functional 4 years later. 
The authors concluded that, in their experience, intraventricular methotrexate is an efficacious 
therapy if conducted under expert neurosurgical care and with meticulous aseptic technique.   
 In 1995, a second retrospective study of 21 adult ALL patients receiving either 
intraventricular (n=9) or intrathecal (n=12) methotrexate for meningeal leukaemia also 
demonstrated a considerable improvement in CNS leukaemia with intraventricular 
methotrexate [44]. In patients receiving intraventricular methotrexate, 89% (8/9) had a 
complete response (CR), defined as complete clinical remission and an absence of malignant 
cells in CSF from two consecutive weekly CSF samples. None of these eight patients had 
further CNS relapse and three had no further events, with a median follow-up of 5 years. By 
comparison, 33% (4/12) of patients receiving intrathecal methotrexate achieved CR, yet two of 
them developed systemic and CNS relapse. The median survival time after intraventricular 
treatment was 152 weeks, compared with 14 weeks for intrathecal therapy (p=0.003). All 
patients receiving intraventricular methotrexate responded to treatment; the single patient who 
did not have a CR had a partial response (defined as a 50% reduction in CSF malignant cells 
with only transient remission). In comparison, 7/12 patients receiving intrathecal methotrexate 
failed to achieve even a partial response to treatment, which greatly affected cohort median 
survival times.  
It is difficult to draw definitive conclusions from so few comparative studies and small 
patient numbers. However, given intraventricular methotrexate has been shown to be more 
effective than intrathecal methotrexate in treating overt meningeal ALL, a multi-centre 
randomized control trial might be warranted to compare the safety and efficacy of 
intraventricular versus intrathecal methotrexate for relapsed/refractory CNS leukaemia.  
 
4. Optimal dosing of methotrexate using Ommaya reservoirs: 
Methotrexate is the cornerstone of CNS-directed therapy in childhood ALL. It inhibits 
dihydrofolate reductase, thereby limiting the availability of reduced folates for purine and 
pyrimidine synthesis, essential for replication [45].  It is important to consider optimal 
concentrations of methotrexate to ensure complete ALL clearance from the CNS, while 
preventing detrimental side effects that can result from overexposure. Based on ex vivo studies 
using human ALL cells, prolonged exposure to methotrexate concentrations >1 μmol/L is more 
important than brief periods of very high methotrexate levels for eradication of leukaemic cells 
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[46]. An emphasis on prolonged leukaemic exposure to methotrexate to optimise cytotoxicity 
is supported by an abundance of pre-clinical work, which is discussed in detail by Ettinger and 
colleagues [47]. The optimal exposure time is thought to be 48-72 hours as the cell cycle takes 
approximately 3 days [48, 49], however, it might be longer in the CNS due to slower 
proliferation kinetics in this microenvironment [50, 51].  
CSF is formed in the choroid plexus of the cerebral ventricles. It flows through the 
subarachnoid space in the spinal column and is reabsorbed into plasma, mostly via the 
arachnoid villi [52]. Several studies have reiterated the observation made by Bleyer et al in 
1973, that active meningeal leukaemia appears to increase methotrexate half-life within CSF 
[53-55]. Grossman and colleagues demonstrated that neoplastic infiltration of the meninges 
results in abnormal CSF flow dynamics, such as ventricular outlet obstructions, spinal canal 
abnormalities and cortical flow delays [56]. Delayed ventricular drainage of methotrexate may 
sustain high concentrations within the ventricles, potentially leading to neurotoxicity. In one 
report, children with overt CNS disease (ALL or non-Hodgkin’s lymphoma) had significantly 
higher CSF methotrexate concentrations compared with children treated prophylactically, 
independent of patient age [54]. A similar study observed normal CSF flow in patients with 
CNS remission [57], suggesting that CSF dynamics are crucially affected by the site and extent 
of meningeal disease. Despite this body of evidence, the clinical implications of these 
observations and how they might impact on rational dosing of CNS-directed therapy are 
unclear and modern ALL protocols do not adjust intrathecal doses based on CNS leukemic 
load.   
There has never been a randomised trial of Ommaya vs lumbar puncture delivery of 
methotrexate. Most studies comparing the two routes were conducted in the 1970s and 1980s 
and are mainly small case series. Despite this, some consistent and important observations 
emerge that help inform decision making on dosing, as detailed below: 
1. Delivery of methotrexate via an Ommaya reservoir results in higher and more consistent 
levels of methotrexate in the cerebral ventricles than delivery via lumbar puncture 
In 1975, Shapiro and colleagues directly compared Ommaya (intraventricular) and lumbar 
puncture (intrathecal) administration of methotrexate and showed that intraventricular delivery 
provided more consistent CSF concentrations when compared to lumbar injection [35]. They 
administered methotrexate with 131I-labelled albumin and subsequently scanned patients at 1-, 
16- and 40-hours post-administration to determine perfusion via the two routes. Methotrexate 
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via Ommaya reservoir was delivered at a dose of 6.25mg/m2, while 6.25mg/m2 and 12.5mg/m2 
doses were compared when given intrathecally via lumbar puncture. From this analysis, they 
observed that despite good CSF flow and manometrics at the time of lumbar puncture, lumbar 
puncture injections were often misplaced and methotrexate failed to enter the CSF. They 
further observed that even when lumbar puncture was successful, there was considerable 
interpatient variability in methotrexate perfusion within the CSF, with up to 100-fold variations 
in intraventricular concentration when administered via intrathecal lumbar injection. 
Furthermore, the larger lumbar dose of 12.5mg/m2 did not correlate with a higher ventricular 
concentration of methotrexate. By comparison, ventricular and lumbar CSF methotrexate 
concentrations were noted to be remarkably consistent when 6.25mg/m2 methotrexate was 
delivered using an Ommaya reservoir. Notably, ventricular and lumbar concentrations of 
methotrexate were maintained above the therapeutic concentration for at least 48 hours when 
using an Ommaya reservoir. They concluded that use of an Ommaya reservoir produces more 
consistent concentrations of methotrexate within the CSF. Other studies have also reported that 
10% of lumbar punctures are misplaced, resulting in inadvertent injection of drugs into the 
epidural or subdural spaces [58]. Whilst Bleyer and colleagues showed that following 
intrathecal delivery of methotrexate, the ventricular concentration of methotrexate reaches just 
10% of the lumbar concentration [36]. Together, these observations suggest that Ommaya 
reservoirs result in more reliable delivery plus significantly higher and more sustained 
methotrexate levels in the cerebral ventricles than the same dose of methotrexate delivered 
intrathecally. Since the current intrathecal doses are known to be efficacious in preventing CNS 
relapse, and there is a risk of neurotoxicity with high doses of methotrexate, this evidence 
supports a reduction of the methotrexate dose when an Ommaya reservoir is used. 
 
2. Use of lower doses of methotrexate via Ommaya reservoirs results in therapeutic CSF 
methotrexate levels in almost all patients  
A reduced dosing strategy was reported by Strother et al in 1989 for administration of 
methotrexate via Ommaya reservoir in 12 children with active meningeal leukaemia [49]. They 
monitored ventricular concentrations of methotrexate, utilising an approach where a smaller 
initial dose (4mg or 6mg) of intraventricular methotrexate is supplemented with further doses 
at 24 or 48 hours, titrated to maintain a therapeutic concentration of methotrexate above 
1umol/L for 72 hours. An initial dose of 6mg methotrexate gave therapeutic CSF methotrexate 
levels in all CSF samples at 24 hours and three-quarters of samples at 48 hours.  The authors 
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emphasised that there is significant intra- and inter-patient variability in the concentrations of 
methotrexate and encouraged the use of therapeutic drug monitoring to titrate doses to 
individual patient requirements. By using this approach, large initial doses of intraventricular 
methotrexate may be avoided without compromising efficacy.   
3. Frequent small doses of methotrexate via Ommaya may optimise pharmacokinetics: 
Earlier work by Bleyer and colleagues in 1978 demonstrated that severe neurotoxicity 
associated with high-dose methotrexate and large cumulative doses of methotrexate delivered 
to the CNS could be avoided by adopting a “Concentration x Time” (CxT) intraventricular 
treatment regimen. Here, smaller doses of methotrexate are given more frequently (1mg/12hr 
for 3 days, repeated weekly) to maintain a therapeutic concentration within the CSF 
(methotrexate concentration >1 μmol/L), while preventing severe neurotoxicity associated with 
larger, less frequent intraventricular doses (12mg/m2, max dose of 15mg, twice-weekly) [36]. 
Importantly, the CxT protocol maintained methotrexate >1 μmol/L, in the therapeutic range 
[46], whereas the large-bolus regimen peaked shortly after administration, before becoming 
sub-therapeutic 32 hours after delivery [36]. Therefore, the CxT protocol demonstrated that 
smaller doses of methotrexate given intraventricularly at regular dosing intervals could 
eliminate high peak concentrations of methotrexate within the CNS (thought to be a risk factor 
for methotrexate-induced neurotoxicity), while maintaining adequate concentrations of 
methotrexate for the duration of the leukaemic cell cycle to optimise cytotoxicity. Strother and 
colleagues noted that studies have consistently failed to demonstrate correlation between higher 
initial methotrexate doses (12mg/m2) and peak, 24- or 48- hour concentrations [35, 36, 47, 48]. 
They advocate a similar approach as Bleyer et al [36], where smaller initial doses are titrated 
based on CSF sampling to maintain methotrexate concentrations >1 μmol/L for at least 72 
hours, thereby maximising therapeutic potential whilst minimising the risk of neurotoxicity.  
Overall, these studies, whilst not conclusive, support reduced dosing for methotrexate 
administered via an Ommaya reservoir, and provide no evidence that use of higher doses leads 
to more sustained therapeutic levels in the CSF.   
 
5. Other intrathecal drugs 
No published literature is available on which to base dosing recommendations for the other 
commonly administered intrathecal drugs for ALL, namely hydrocortisone and cytarabine. 
Based on the discussion above, it seems reasonable to extrapolate findings from 
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pharmacokinetic studies of methotrexate to other anti-leukaemic drugs whose dosing was 
originally established for intrathecal use via lumbar puncture. Thus, we would advocate 50% 
dosing for all three drugs when triple intrathecal therapy is administered, although we note that 
this is not evidence-based.  This is consistent with current recommendations on the Children’s 
Oncology Group trials in the USA (information obtained from clinical trial protocols, 
unpublished).  
 
6. Future recommendations: 
In the absence of definitive level I evidence to guide clinical decision making, our 
recommendation is based on the available published evidence. Only centres with expert 
paediatric neurosurgeons and experience of implanting Ommaya reservoirs should attempt 
insertion. Adequate MRI neuroimaging of the brain and spinal cord should be carried out 
shortly before neurosurgical implantation. Adequate staff training, and a meticulous aseptic 
protocol should be followed to minimise the risk of CNS infection. Centres using Ommaya 
reservoirs should conduct continuous, thorough clinical audits to identify areas of clinical 
concern for directed improvement.    
Overall, the literature supports dose reductions when using intraventricular 
methotrexate, compared with intrathecal methotrexate, owing to improved CSF distribution 
resulting in higher ventricular methotrexate concentrations. While CxT dosing regimens, with 
daily low-dose methotrexate [36] may produce optimal methotrexate concentrations, the safety 
and efficacy of this regimen has not been verified in a large cohort of children. Additionally, 
repeated Ommaya access is consistently associated with increased rates of infection [12]. As 
discussed above, in most children a single dose of 50% of the intrathecal dose led to sustained 
therapeutic concentrations in the CSF for at least 48 hours.  Monitoring of levels and 
administration of top-up methotrexate at 24 and 48 hours could be considered best practice but 
since similar monitoring and dose modifications are not currently in place for intrathecal 
methotrexate, its adoption in front-line ALL CNS prophylaxis protocols could be considered a 
treatment escalation. Therefore, in these situations, we recommend that methotrexate via 
Ommaya reservoir be administered at 50% of the intrathecal dose, at the same treatment 
intervals without therapeutic drug monitoring. For patients with relapsed or refractory CNS 
leukaemia a fractionated CxT approach or use of 50% dosing with monitoring of levels and 
“top-ups” as needed should be considered on a case-by-case basis. 
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It is clear from the above that further research on this topic is required. Priorities for 
further investigation would a prospective registry of ALL patients with Ommaya reservoirs 
capturing indication, dosing regimen, complications and outcome. In addition, given the 
encouraging historical data suggesting that Ommaya reservoir use results in longer remission 
[43, 44] and may be preferred by patients [42], an RCT of Ommaya vs intrathecal methotrexate 
for relapsed CNS ALL (as part of a systemic multiagent chemotherapy approach) is desirable.      
This data was presented and discussed at the UK Childhood Leukaemia Clinicians 
Network meeting on the 23rd May 2017. A pragmatic consensus decision was made to 
recommend administration of 50% doses of all intrathecal chemotherapy to any child requiring 
intraventricular administration of CNS-directed therapy on front-line ALL protocols, pending 
any further published evidence to guide rational evidence-based dosing. 
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Table 1: Advantages and limitations of using Ommaya reservoirs in place of repeated 
intrathecal injections for administering methotrexate to the CNS.  
 
Advantages: Limitations: 
Ease of access to CSF for repeated drug delivery 
Reduced risk of misplaced drug delivery 
No requirement for general anaesthesia  
Improved CSF distribution of drug  
Possibly improved efficacy 
CSF sampling allows for dose titration 
Reduced frequency of lumbar puncture 
CNS infection risk  
Increased neuroimaging 
Risk of misplaced catheter 
Risk of tumour seeding (solid tumours) 
Bleeding risk 
Risk of further neurosurgery 
Risk of catheter occlusion 
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Figure 1: This pie chart represents the 20 responses obtained from our survey of 21 UK 
Paediatric Principal Treatment Centres. Dosing percentages are compared to age-appropriate 
intrathecal (IT) doses of methotrexate advocated in modern UKALL clinical trials. 8/21 centres 
used 100% of the intrathecal methotrexate dose when using an Ommaya reservoir for CNS 
access, 5/21 centres used 50% dosing, 3/21 centres previously used 2mg as a single dose, 4/21 
centres did not use Ommaya reservoirs and 1 centre did not respond to our survey. *Of the 3 
centres previously using 2mg dosing, they have advised that they have since changed their 
practice, with 2 centres now opting for 50% dosing and 1 centre now using 100% dosing.  
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